Acasti Pharma (NASDAQ:ACST) has been struggling to regain its levels seen last June. There were delays in releasing results for TRILOGY 2. But the announcement yesterday that a second Phase 3 clinical trial was unsuccessful resulted in Acasti Pharma shares collapse by over 60%. But this collapse was anticipated by Elliott Waves, although I was…